Urbain Tauveron-Jalenques

4PUBLICATIONS
13CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Mar 25, 2026
Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Zofia Gross

|Nov 30, 2024
Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.

Urbain Tauveron-Jalenques, Khadim Sarr, Romain Guièze

Pageof 1

Frequent Collaborators

2 joint publications

Gaspar Requena Aspas

2 joint publications

Emmanuelle Tavernier

2 joint publications

Mauricette Michallet

1 joint publications

Pedro Chorão